Skip to main navigation
Skip to main content
Schrödinger

    Client Secondary Menu

  • Download
  • Contact
  • Support

    About

  • About
      • Team
      • Our Story
      • Culture
      • Diversity & Inclusion
      • Platform

      • Platform
          • Overview
          • Drug Discovery
          • Materials Science
          • All Products A-Z
          • Publications
          • Pipeline

          • Pipeline
          • User Events

          • User Events
          • Careers

          • Careers
          • Investor Relations (Sub Menu)

          • Investor Relations
              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

                Investor Relations (Sub Menu)

              • Overview
              • News & Events
              • Presentations
              • Stock Information
              • Corporate Governance
              • Shareholder Services
              • SEC Filings

              Press Releases

              News & Events ( third-level-submenu)

              • Press Releases
              • Event Calendar

              Press Releases

              Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

              NEW YORK --(BUSINESS WIRE)--Dec. 7, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62 nd  
              December 7, 2020
              • Read More

              Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb

              Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties NEW YORK --(BUSINESS WIRE)--Nov. 23, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are
              November 23, 2020
              • Read More

              Schrödinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update

              Total revenue of $25.8 million , up 29% year-over-year; Software revenue of $22.9 million , up 42% year-over-year Raised $325.6 million net proceeds in equity financing Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition Conference
              November 12, 2020
              • Read More

              Schrödinger to Present at Upcoming Investor Conferences

              NEW YORK --(BUSINESS WIRE)--Nov. 10, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the management team will participate in the upcoming virtual investor conferences in
              November 10, 2020
              • Read More

              Schrödinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

              NEW YORK --(BUSINESS WIRE)--Nov. 5, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of
              November 5, 2020
              • Read More

              Schrödinger to Host Third Quarter 2020 Financial Results Conference Call and Webcast

              NEW YORK --(BUSINESS WIRE)--Nov. 5, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 a.m.
              November 5, 2020
              • Read More

              Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

              NEW YORK --(BUSINESS WIRE)--Sep. 8, 2020-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Morgan
              September 8, 2020
              • Read More

              Schrödinger Announces Closing of Public Offering

              NEW YORK --(BUSINESS WIRE)--Aug. 17, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the closing of its underwritten
              August 17, 2020
              • Read More

              Schrödinger Announces Pricing of Public Offering

              NEW YORK --(BUSINESS WIRE)--Aug. 12, 2020-- Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the pricing of an underwritten
              August 12, 2020
              • Read More

              Schrödinger Announces Proposed Public Offering of Common Stock

              NEW YORK --(BUSINESS WIRE)--Aug. 10, 2020-- Schrödinger, Inc. (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, today announced the commencement of a proposed underwritten public
              August 10, 2020
              • Read More

              Pagination

              • Current page 1
              • Page 2
              • Page 3
              • Next page next ›
              • Last page last »
              Displaying 1 - 10 of 25

              Investor Tools

              • Email Alerts
              • Email Alerts
              • Investor Contact
              • Investor Contact
              • Print Page
              • Print Page
              • Email Page
              • Email Page

              Social Menu

              Twitter Youtube} Google Linkedin

              Copyright © 2021 Schrödinger, Inc.

                Legal Menu

              • Citations
              • Privacy Policies
              • Terms of Use
              • FCOI Policy
              • EULA
              Back To Top